Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
UI-102 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| UI-102 Monotherapy, IV infusion | EXPERIMENTAL | UI-102 monotherapy administered intravenously. This arm includes Phase I dose escalation, backfill cohorts, and cohort expansion in participants with selected locally advanced and/or metastatic solid tumors. |
| UI-102 Combination Therapy, IV infusion | EXPERIMENTAL | UI-102 administered intravenously in combination with standard-of-care agents commonly used. This arm includes dose escalation, dose optimization, and cohort expansion. |
| Name | Type | Description |
|---|---|---|
| UI-102 | DRUG | Specified dose on specified days |
Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, * 18 Years and Older (adult, older adult), * Histologically confirmed advanced cancer, * Archived or fresh tumor tissue sample that must be confirmed as adequate, * Evaluable/Measurable disease per R...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
UI-102 is an investigational small molecule being developed for the treatment of advanced cancer. It is currently in Phase 1 clinical development, with a Phase 1/2 study evaluating its use in selected advanced cancers. The drug is not yet approved and is still being tested in clinical trials.
UI-102 is being developed by United Therapeutics Corporation, a biotechnology company traded on the NASDAQ under the ticker symbol UTHR. The company is conducting clinical trials to evaluate the safety and efficacy of UI-102 in patients with advanced cancer.
UI-102 is currently in Phase 1 clinical development. A Phase 1/2 study is recruiting participants to evaluate the drug in selected advanced cancers. As an investigational agent, UI-102 has not yet received regulatory approval and is still undergoing clinical testing.
UI-102 is being studied in a Phase 1/2 clinical trial with the identifier NCT07605962, titled 'Phase 1/2 Study of UI-102 in Selected Advanced Cancers.' This trial is currently recruiting participants in the United States and aims to enroll approximately 140 patients with advanced cancer.
No, UI-102 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The ongoing Phase 1/2 trial is evaluating its safety and efficacy in patients with advanced cancer, but regulatory approval has not been granted.